In 2013, a threat to cuts in government funding loomed over life science companies. The aftermath of this scenario could affect scores of breakthroughs, including life-improving drugs, devices, and innovation in genome sequencing. This “leave-behind” was created to educate lobbyists on the ramifications of such cuts and persuade them to vote otherwise.
